Investing.com - Cytek Biosciences (NASDAQ: CTKB) reported first quarter EPS of $-0.05, $0.07 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $37.1M versus the consensus estimate of $47.17M.
Guidance
Cytek Biosciences sees FY 2023 revenue of $205.00M-$220.00M versus the analyst consensus of $228.20M.
Cytek Biosciences's stock price closed at $11.67. It is down -8.33% in the last 3 months and up 45.15% in the last 12 months.
Cytek Biosciences saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Cytek Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Cytek Biosciences's Financial Health score is "good performance".
Check out Cytek Biosciences's recent earnings performance, and Cytek Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar